Ventana's Promising New Anti-Obesity Patent
28 Juli 2009 - 8:21PM
Marketwired
Ventana Biotech Inc ("Ventana")(PINK SHEETS: VNTA), a biotechnology
company that is developing a appetite-suppressing chewing gum,
today released detailed information about its innovative
Anti-Obesity Chewing Gum.
The goal of Ventana's Anti-Obesity Chewing Gum is to combat the
growing global obesity epidemic while capturing a share of the
multi-billion dollar market for anti-obesity drugs.
How it works
Ventana's proprietary chewing gum contains an extract of hoodia
gordonii and 2-hydroxyoleic acid. Hoodia gordonii is a leafless,
cactus-like plant that grows naturally in Southern Africa that was
historically used by native populations to suppress appetite when
making long hunting trips in the Kalahari Desert. The plant has
also been found to possess the ability to lower blood glucose
levels, thereby also making it an attractive candidate for the
treatment and prevention of diabetes.
The active ingredients in the plant extracts are released into
the patient's blood stream, and trigger a hormonal response in the
part of the brain (the hypothalamus) that tells the body it is
"full", thereby suppressing the appetite of the obese patient.
Because the plant extracts activate hormones that naturally exist
in the body, there are no harmful side effects.
The simple logic is that the Anti-Obesity Chewing Gum eliminates
the feeling of "hunger", which in turn leads the patient to ingest
less food, which in turn leads to weight loss.
Obesity is a growing problem in developed nations, and is
associated with increased mortality, Type 2 Diabetes, and heart
disease.
With Ventana's proprietary Anti-Obesity Chewing Gum, users can
safely control their appetites. Early indications show the Gum is
able to reduce appetite by between 15 and 25 percent. Ventana
continues to perfect this promising biotechnology and plans to
eventually out-license it to Big Pharma companies. The royalty
cash-flow from a successful anti-obesity drug is estimated at 1.5 -
1.7 billion Dollars.
The outlook for anti-obesity treatments such as that of
Ventana's is promising, as the anti-obesity market continues to
grow, while concurrently, the availability of successful patents is
lacking. Morgan Stanley estimates the market for drugs combating
Type 2 Diabetes (strongly correlated to obesity) to be in excess of
$35 billion by 2012.
About Ventana Biotech Inc
Ventana is positioning itself as the leading bioscience company
in the development and commercial licensure of novel therapeutic
anti-obesity drug treatment. The company leverages cutting-edge
research collaborations to achieve breakthroughs in innovative
anti-obesity treatments, and then licenses these patented drug
product candidates to Big Pharmaceutical and Biotechnology
companies.
FORWARD-LOOKING STATEMENTS:
Statements about Ventana's future expectations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as the term is defined in the Private Litigation
Reform Act of 1995. Ventana's actual results could differ
materially from expected results. Ventana does not undertake any
obligation to update forward-looking statements to reflect
subsequently occurring events or circumstances. Should events occur
which materially affect any comments made within this objective;
Ventana will appropriately inform the public.
For more information about Ventana Biotech Inc please contact
investor@ventanabiotech.com
Contacts: Ventana Biotech Inc Janne Christensen CEO + 41 44 732
6059 investor@ventanabiotech.com
Ventana Biotech (PK) (USOTC:VNTA)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Ventana Biotech (PK) (USOTC:VNTA)
Historical Stock Chart
Von Jun 2023 bis Jun 2024